lexapro has been researched along with quinidine in 1 studies
| Studies (lexapro) | Trials (lexapro) | Recent Studies (post-2010) (lexapro) | Studies (quinidine) | Trials (quinidine) | Recent Studies (post-2010) (quinidine) |
|---|---|---|---|---|---|
| 17 | 0 | 12 | 6,608 | 387 | 594 |
| Protein | Taxonomy | lexapro (IC50) | quinidine (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 6.4 | |
| Cholinesterase | Homo sapiens (human) | 1.23 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 3.32 | |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | 2.8 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.3532 | |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | 7.3 | |
| Cholinesterase | Equus caballus (horse) | 7.37 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 6.4 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.7882 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 6.4 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 6.4 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 6.9 | |
| Potassium voltage-gated channel subfamily D member 2 | Rattus norvegicus (Norway rat) | 2.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for lexapro and quinidine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |